Medical device innovation demands time, evidence – and smart capital.
Swissrehamed GmbH has invested years of research and patient-focused development into robotic aquatic therapy systems such as ascros™, craPos™, and cranos™. These technologies offer value not just for patients and therapists – but also for investors who believe in long-term, purpose-driven health innovation.
We welcome partners who:
• value mid- and long-term impact over short-term speculation
• believe in real-world clinical value and patient-perceived outcomes
• are open to radically new financing models beyond the conventional startup pitch cycle
Our journey has led us to rethink how innovation is valued – not just in terms of IRR or DCF, but through a concept we call:
IPV – Investor Perceived Value,
inspired by PPV (Patient), DPV (Doctor) and TPV (Therapist) frameworks.
If you are interested in this next-generation venture logic –
driven by health equity, research-backed solutions and stakeholder alignment –
we invite you to explore our thinking:
→ Read the story: Looking for new ways in funding a great solution
→ Join the mission and help shape the next financing chapter of Swissrehamed.
Ascros Inc. is a U.S.-based spin-off of Swissrehamed GmbH, legally incorporated in Delaware and strategically operating from Boston, Massachusetts.
The company is built to:
Scale the ascros™ system as a modular, FDA-aligned Class IIb robotic rehabilitation device
Launch and operate NAMRU (Neurological Aqua Mobile Research Unit) for clinical trials in underserved regions
Extend the reach of Swiss innovation to U.S. patients, hospitals, and research centers
Incorporation
• Location: Delaware, USA
• Entity: Ascros Inc. (C‑Corp)
U.S. Operating Base
• Location: Boston, Massachusetts
• Entity: Ascros Inc. (Boston Office)
IP Origin & Licensing Base
• Location: Switzerland
• Entity: Swissrehamed GmbH
✅ Delaware is the U.S. standard for startup-friendly legal frameworks, investor onboarding, and equity instruments (SAFE, convertible notes).
✅ Boston offers access to top-tier rehabilitation centers, venture ecosystems, and university collaborators (e.g., MIT, MGH, Spaulding).
✅ IP remains protected under Swiss law while licensed to Ascros Inc. for commercialization.
Swiss and international investors are invited to join via:
LVC-SAFE convertible notes (Liechtenstein cooperative framework)
Strategic equity rounds in Ascros Inc. (Delaware C-Corp)
🧩 All modules (ascros™, NAMRU, ECP-UGC™) are prepared for FDA and MDR pathways, backed by a robust IP and regulatory strategy.